Innovation Pharmaceuticals Inc (IPIX)

[loanranger]

I don't know....and I'm not sure that the company knows either. I found nothing specific not to like.

It's unusual to see such a short term contract (one year) with a new senior officer. This may suggest that he's being brought in for a specific project or purpose or that the company isn't inclined to commit to a third "partner" without a test run. That said, "Dr. Alexander had been serving Cellceutix as a medical consultant since 2012", so it's not like he's an unknown entity.

"From July 2008 to present he operated as a sole proprietorship under the name of Alexander Pharma Consulting, LLC". I was unable to connect him to any clients in a simple search for that firm.

CTIX says:
"From June 2006 to June 2008 he served as Vice President, Clinical Development at BioCryst Pharmaceuticals."
BioCryst filings say this:
"W. James Alexander, M.D., M.P.H joined BioCryst in June 2006 as Senior Vice President, Clinical and Regulatory Operations and Chief Medical Officer."
and expand a little on his background:
"Prior to joining the Company, Dr. Alexander was Senior Vice President, Product Development at POZEN from November 2003 to June 2006. Dr. Alexander was Chief Medical Officer of Inveresk Research Group from July 2003 to October 2003. From 1998 to 2003, Dr. Alexander was Chief Medical/Regulatory Officer at PharmaResearch Corporation, with global responsibilities for medical and regulatory operations and he also served as President from 1998-1999, Chief Executive Officer from 1999-2000 and was Chairman of the Board of PharmaReseach Corporation from 2000 to 2003. From 1996 to 1998, he served as Vice President and Director, Worldwide Product Safety and Pharmacovigilance at GlaxoWellcome, Inc. Dr. Alexander received a B.S. from Mississippi State University, his M.D. from the University of Mississippi and his M.P.H. from the University of Alabama at Birmingham. He is board certified in internal medicine and infectious diseases."

I'm not sure whether there's any significance to the fact that he was hired by BioCryst as Chief Medical Officer in 2006 and replaced without any explanation that I saw in January of 2008. The change resulted in Mr. Alexander's no longer being an Officer of that corporation.
http://www.sec.gov/Archives/edgar/data/882796/000136231008000090/c72043e8vk.htm
http://www.sec.gov/Archives/edgar/data/882796/000136231008000090/c72043exv99w1.htm

Searching BioCrysts website showed him being attached to their flu drug, peramivir.
("In December 2013, BioCryst submitted a NDA filing for i.v. peramivir to the U.S. Food & Drug Administration (“FDA”) seeking an indication as the first i.v. neuraminidase inhibitor approved in the U.S. for the treatment of acute uncomplicated influenza in adults. On February 24, 2014, the FDA notified the Company its NDA submission had been accepted for review. The FDA is expected to take action on the application by December 23, 2014.")
http://investor.shareholder.com/biocryst/secfiling.cfm?filingID=1171843-14-3839

Since he is no longer an Officer of that company his name has disappeared from their 10-K's. I can't tell whether he is still connected to them in any way.



ps. I think you can safely ignore any connection to "uplisting". He's not being brought on as a Director and has no financial expertise. As an employee he wouldn't qualify as an independent director anyway...and that's what is needed.